top of page

Alzheimer's disease testing innovation

The IMPACT-AD team's Alzheimer's disease testing innovation for amyloid-beta proteoforms has been published in a leading scientific journal!

The first method to identify both sporadic and autosomal dominant Alzheimer's disease

This is the first method to identify both sporadic AD (by wt-Aβ42 and wt-Aβ40 concentration) and autosomal dominant AD (by identification of pathogenic APP variants) in one anatysis, enabling biomarker testing without a priori knowledge of the genetic makeup of an individual.

Fully-automated & calibrated to the international standard

Development of an automated workflow and selection of appropriate instrumentation enabled deployment of this method for routine patient testing in Canada!


Commenting has been turned off.
bottom of page